written by reader Vericel- Potential of MACI

By eneels01, January 3, 2017

Can management fully execute on capturing 20k MACI procedures (for knee cartilage repair)? Microfracture procedure costs much less, but MACI has proven superior in a clinical trial. The company’s CEO sees an opportunity to grow from 1100 (former carticel) procedures to as much as 20k/ yr (recent FDA approved MACI procedures). Competition is not seen for at least 3 years. In terms of stock price, I see a potential for $8 by EOY 2017 as Q4 should be EPS positive if the company can execute. Any thoughts?

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.